


Status: Currently Official on 14-Feb-2025  
 Official Date: Official as of 01-May-2020  
 Document Type: USP Monographs  
 DocId: GUID-F330AF2E-C1D4-4F33-908D-9ED8FC938EAB\_2\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M3063\\_02\\_01](https://doi.org/10.31003/USPNF_M3063_02_01)  
 DOI Ref: f6khm

© 2025 USPC  
 Do not distribute

## Ecamsule Solution



$C_{28}H_{34}O_8S_2$  562.69

Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 3,3'-(1,4-phenylenedimethyldiene)bis[7,7-dimethyl-2-oxo]-.

(±)-(3E,3'E)-3,3'-(p-Phenylenedimethyldiene)bis[2-oxo-10-bornanesulfonic acid] CAS RN®: 92761-26-7; UNII: M94R1PM439.

» Ecamsule Solution is an aqueous solution of  $C_{28}H_{34}O_8S_2$ . It contains not less than 30.0 percent and not more than 34.0 percent, by weight, of ecamsule ( $C_{28}H_{34}O_8S_2$ ).

**Packaging and storage**—Preserve in tight containers. Protect from light, and store at room temperature.

**USP REFERENCE STANDARDS (11).**—

[USP Ecamsule Solution RS](#)

[USP Ecamsule Related Compound A RS](#)

1,4-Phenylenedimethanol.

$C_8H_{10}O_2$  138.16

[USP Ecamsule Related Compound B RS](#)

4-(Hydroxymethyl)benzoic acid.

$C_8H_8O_3$  152.15

[USP Ecamsule Related Compound C RS](#)

Terephthalic acid.

$C_8H_6O_4$  166.13

[USP Ecamsule Related Compound D RS](#)

((1S,4R)-7,7-Dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonic acid.

$C_{10}H_{16}O_4S$  232.30

[USP Ecamsule Related Compound E RS](#)

Sodium ((1S,4SR,E)-3-(4-(hydroxymethyl)benzylidene)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate.

$C_{18}H_{21}NaO_5S$  372.41

[USP Ecamsule Related Compound F RS](#)

4-((E)-((1S,4SR)-7,7-Dimethyl-3-oxo-4-(sulfomethyl)bicyclo[2.2.1]heptan-2-ylidene)methyl)benzoic acid.

$C_{18}H_{20}O_6S$  364.41

[USP Ecamsule Related Compound G RS](#)

4-((E)-((1S,4SR)-7,7-Dimethyl-3-oxo-4-(sulfomethyl)bicyclo[2.2.1]heptan-2-ylidene)methyl)benzaldehyde, sodium salt.

$C_{18}H_{19}NaO_5S$  370.40

[USP Ecamsule Triethanolamine RS](#)

Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 3,3'-(1,4-phenylenedimethyldiene)bis[7,7-dimethyl-2-oxo]-, ditriethanolamine salt (1:2).

$C_{28}H_{34}O_8S_2 \cdot (C_6H_{15}NO_3)_2$  861.07

**Labeling**—The label states that this article is not intended for direct administration to humans or animals.

**Identification**—

**Change to read:**

**A:** [▲Spectroscopic Identification Tests \(197\), Infrared Spectroscopy: 197A](#) (CN 1-May-2020) —Place a drop of Ecamsule Solution on a diamond sampling surface and dry it with a stream of warm air. The IR absorption spectrum conforms to that of [USP Ecamsule Solution RS](#), similarly obtained.

**Change to read:**

**B:** [▲SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Ultraviolet-Visible Spectroscopy: 197U](#) (CN 1-May-2020) —

**Solution**—Transfer 0.25 g of Ecamsule Solution to a 100-mL volumetric flask, and dilute with water to volume. Further dilute 2 mL of this solution with water to 100 mL.

The **Solution** exhibits absorption maximum between 342 and 346 nm.

**Limit of chloride**—Dissolve about 10 g of Ecamsule Solution, accurately weighed, in 70 mL of water. Titrate this solution with 0.01 N silver nitrate, determine the endpoint potentiometrically (see [Titrimetry \(541\)](#)), and calculate the percentage of chloride in the portion of  $C_{28}H_{34}O_8S_2$  taken by the formula:

$$100(35.5)(VN/W)(100/A)$$

in which 35.5 is the atomic weight, in g per mole, of chloride; V is the volume, in mL, of silver nitrate used for titration; N is the concentration, in normality, of silver nitrate; W is the weight, in mg, of Ecamsule Solution taken for determination; and A is the assay, in percent, of Ecamsule Solution: not more than 0.3% of chloride is found.

**Limit of sodium**—

*Diluent*—Transfer 5 mL of nitric acid in a 1000-mL volumetric flask containing about 500 mL of water, and dilute with water to volume.

*Test solution*—Transfer about 1 g of Ecamsule Solution, accurately weighed, to a 100-mL volumetric flask, and dilute with *Diluent* to volume.

*Standard solutions*—Dilute quantitatively, and stepwise if necessary, a commercially available sodium atomic absorption standard solution containing 1000 µg of sodium per mL with *Diluent* to obtain solutions having known concentrations of 1, 5, 10, and 20 µg per mL, respectively.

*Procedure* (see [ATOMIC ABSORPTION SPECTROSCOPY \(852\)](#))—Concomitantly determine the absorbances of the *Standard solutions* and the *Test solution* at the sodium emission line of 330 nm or 589 nm with a suitable atomic absorption spectrophotometer equipped with a sodium lamp and an air–acetylene flame, using *Diluent* as the blank. Determine the concentration of sodium, in µg per mL, in the *Test solution* using the calibration graph. Calculate the percentage of sodium in the portion of  $C_{28}H_{34}O_8S_2$  taken by the formula:

$$100 \times 10^{-6}(CV/W)(100/A)$$

in which C is the concentration, in µg per mL, of sodium in the *Test solution*, the multiplier of  $10^{-6}$  is for conversion of µg per mL to g per mL; V is the volume, in mL, of *Test solution*; W is the weight, in g, of Ecamsule Solution taken for determination; and A is the assay, in percent, of Ecamsule Solution: not more than 0.3% of sodium is found.

**Related compounds**—

*Test for related compounds A to F*—

*Solvent A*—Prepare a mixture of acetonitrile and 85% phosphoric acid (1000:1).

*Solvent B*—Prepare a mixture of water and 85% phosphoric acid (1000:1).

*Standard solution*—Dissolve an accurately weighed quantity of [USP Ecamsule Related Compound A RS](#), [USP Ecamsule Related Compound B RS](#), [USP Ecamsule Related Compound C RS](#), [USP Ecamsule Related Compound D RS](#), [USP Ecamsule Related Compound E RS](#), and [USP Ecamsule Related Compound F RS](#) in water, sonicating if necessary, to obtain a solution having known concentrations as found in [Table 1](#).

*Test solution*—Transfer about 100 mg, accurately weighed, of Ecamsule Solution to a 50-mL volumetric flask, and dilute with water to volume.

*Chromatographic system* (see [CHROMATOGRAPHY \(621\)](#))— The liquid chromatograph is equipped with either a programmable variable wavelength detector or two separate detectors capable of monitoring at 200 nm and 300 nm and a 4.6-mm × 15-cm column that contains 5-µm packing L1. The flow rate is about 1 mL per minute. The chromatograph is programmed as follows.

Time (minutes)	Solution A (%)	Solution B (%)	Elution
0–25	20	80	isocratic
25–27	20→80	80→20	linear gradient
27–47	80	20	isocratic
47–50	80→20	20→80	linear gradient
50–65	20	80	equilibration

Chromatograph the *Standard solution*, and record the peak areas as directed for *Procedure*: the relative standard deviations of the ecamsule related compound peaks for replicate injections are not more than 10.0%; and the resolution, *R*, between all adjacent peak pairs of ecamsule related compounds is not less than 1.5 measured at 200 nm.

*Procedure*—Separately inject equal volumes (about 10 µL) of the *Standard solution* and the *Test solution* into the chromatograph, allow the chromatogram to run for about 20 minutes for the *Standard solution* and 60 minutes for the *Test solution*, record the chromatograms at 200 nm from 0 to 8 minutes and at 300 nm after 8 minutes, and measure the peak areas. Calculate the percentage of ecamsule related compounds A, B, C, D, and F in the portion of  $C_{28}H_{34}O_8S_2$  taken by the formula:

$$100[100C_s/(C_u \times A)](r_u/r_s)$$

in which  $C_s$  is the concentration, in mg per mL, of the ecamsule related compound in the *Standard solution*;  $C_u$  is the concentration, in mg per mL, of the *Test solution*; A is the assay, in percent, obtained from the Assay; and  $r_u$  and  $r_s$  are the peak areas of the ecamsule related

compound obtained from the *Test solution* and *Standard solution*, respectively. Calculate the percentage of ecamsule related compound E in the portion of  $C_{28}H_{34}O_8S_2$  taken by the formula:

$$100(350.43/372.41)[100C_s/(C_U \times A)](r_U/r_s)$$

in which 350.43 and 372.41 are the molecular weights of ecamsule related compound E (free acid) and [USP Ecamsule Related Compound E RS](#) (sodium salt), respectively;  $C_s$  is the concentration, in mg per mL, of ecamsule related compound E in the *Standard solution*;  $C_U$  is the concentration, in mg per mL, of the *Test solution*; A is the assay, in percent, obtained from the Assay; and  $r_U$  and  $r_s$  are the peak areas of the ecamsule related compound E obtained from the *Test solution* and *Standard solution*, respectively. The limits are given in [Table 1](#).

Table 1

Name	Concentration (mg/mL) in the Standard solution	Detection wavelength (nm)	RRT <sup>1</sup>	Limit (%)
Ecamsule related compound A	0.001	200	0.42	0.2
Ecamsule related compound B	0.001	200	0.54	0.2
Ecamsule related compound C	0.001	200	0.70	0.2
Ecamsule related compound D	0.008	200	1.00	1.3
Ecamsule related compound E (free acid)	0.004	300	2.52	0.7
Ecamsule related compound F	0.004	300	3.26	0.7

<sup>1</sup> Ecamsule elutes after 27 minutes and is a broad peak in the *Test for related compounds A to F*. The relative retention times of related compounds are measured with respect to ecamsule related compound D.

*Test for related compound G, Ecamsule exo-2-hydroxyecamsule, Ecamsule endo-2-hydroxyecamsule, and unspecified impurities—*

*Mobile phase—*Proceed as directed in the Assay.

*Standard solution 1—*Dissolve an accurately weighed quantity of [USP Ecamsule Related Compound G RS](#) in water to obtain a solution having a known concentration of about 0.005 mg per mL.

*Standard solution 2—*Use the *Standard preparation*, as described in the Assay.

*Test solution—*Use the *Assay preparation*, prepared as directed in the Assay.

*Chromatographic system—*Prepared as directed in the Assay. Use the liquid chromatograph equipped with a 310-nm detector in addition to using a 343-nm detector. [NOTE—Ecamsule related compound G is detected at 310 nm; and Ecamsule exo-2-hydroxyecamsule, Ecamsule endo-2-hydroxyecamsule, and unspecified impurities are detected at 343 nm.]

*Procedure—*Separately inject equal volumes (about 20 µL) of *Standard solution 1*, *Standard solution 2*, and the *Test solution* into a chromatograph, record the chromatograms for not less than 6 times the retention time of ecamsule trans-trans isomer, and measure the peak areas. Calculate the percentage of ecamsule related compound G in the portion of  $C_{28}H_{34}O_8S_2$  taken by the formula:

$$100(348.41/370.40)[100C_s/(C_U \times A)](r_U/r_s)$$

in which 348.41 and 370.40 are the molecular weights of ecamsule related compound G and [USP Ecamsule Related Compound G RS](#), respectively;  $C_s$  is the concentration, in mg per mL, of [USP Ecamsule Related Compound G RS](#) in *Standard solution 1*;  $C_U$  is the concentration, in mg per mL, of the *Test solution*; A is the assay, in percent, obtained from the Assay; and  $r_U$  and  $r_s$  are the peak areas of ecamsule related compound G obtained from the *Test solution* and *Standard solution 1*, respectively. Calculate the percentage of Ecamsule exo-2-hydroxyecamsule and Ecamsule endo-2-hydroxyecamsule in the portion of  $C_{28}H_{34}O_8S_2$  taken by the formula:

$$100(1/F)[100C_s/(C_U \times A)](r_i/r_s)$$

in which F is the relative response factor for each impurity obtained from [Table 2](#);  $C_s$  is the concentration, in mg per mL, of [USP Ecamsule](#)

Triethanolamine RS in *Standard solution 2*;  $C_U$  is the concentration, in mg per mL, of the *Test solution*;  $A$  is the assay, in percent, obtained from the *Assay*;  $r_i$  is the peak area for each impurity obtained from the *Test solution*; and  $r_s$  is the sum of peak areas corresponding to the trans-trans and cis-trans isomers obtained from the *Standard solution*. Calculate the percentage of any unspecified impurity in the portion of  $C_{28}H_{34}O_8S_2$  taken by the formula:

$$100(r_i/r_s)$$

in which  $r_i$  is the peak area for each unspecified impurity obtained from the *Test solution*; and  $r_s$  is the sum of all peak areas obtained from the *Test solution*. The limits are given in [Table 2](#).

Table 2

Name	RRT <sup>3</sup>	F	Limit (%)
Ecamsule related compound G	0.9	—	0.2
Ecamsule exo-2-hydroxyecamsule <sup>1</sup>	1.4	0.6	0.2
Ecamsule endo-2-hydroxyecamsule <sup>2</sup>	1.6	0.6	0.3
Any single unspecified impurity	—	1.0	0.5

<sup>1</sup> [(1SR,2R,4SR,E)-3-(4-((E)-[(1SR,4SR)-7,7-dimethyl-3-oxo-4-(sulfomethyl)bicyclo[2.2.1]heptan-2-ylidene)methyl]benzylidene)-2-hydroxy-7,7-dimethylbicyclo[2.2.1]heptan-1-yl)methanesulfonic acid [ $C_{28}H_{36}O_8S_2$ , 564.71].

<sup>2</sup> [(1SR,2S,4SR,E)-3-(4-((E)-[(1SR,4SR)-7,7-dimethyl-3-oxo-4-(sulfomethyl)bicyclo[2.2.1]heptan-2-ylidene)methyl]benzylidene)-2-hydroxy-7,7-dimethylbicyclo[2.2.1]heptan-1-yl)methanesulfonic acid [ $C_{28}H_{36}O_8S_2$ , 564.71].

<sup>3</sup> The relative retention times are measured with respect to ecamsule trans-trans isomer.

*Total impurities*—Calculate the sum of the related compounds and unspecified impurities from the *Test for related compounds A to F* and the *Test for related compound G, Ecamsule exo-2-hydroxyecamsule, Ecamsule endo-2-hydroxyecamsule, and unspecified impurities*: not more than 5.0% of total impurities is found.

**Assay**— [NOTE—Prepare solutions immediately before use, and protect them from light in low-actinic glassware.]

*1% Triethylamine solution*—Prepare a mixture of water and triethylamine (100:1), and adjust with phosphoric acid to a pH of 7.

*Mobile phase*—Prepare a mixture of 1% *Triethylamine solution* and methanol (50:50). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

*Standard preparation*—Dissolve an accurately weighed quantity of [USP Ecamsule Triethanolamine RS](#) in *Mobile phase*, sonicating if necessary, to obtain a solution having a known concentration of about 0.12 mg per mL of ecamsule triethanolamine.

*Assay preparation*—Transfer about 500 mg, accurately weighed, of Ecamsule Solution to a 100-mL volumetric flask, and dilute with water to volume. Transfer 5.0 mL of this solution into a 100-mL volumetric flask, and dilute with water to volume.

*Chromatographic system* (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 343-nm detector and a 4.0-mm × 125-mm column that contains 5-μm packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the relative retention times are about 1.0 for ecamsule trans-trans isomer and 2.9 for the ecamsule cis-trans isomer; the relative standard deviation of the sum of the ecamsule trans-trans and cis-trans peak areas for replicate injections is not more than 2.0%; and the number of theoretical plates of the peak corresponding to the trans-trans isomer is not less than 1430.

*Procedure*—Inject equal volumes (about 20 μL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the peak areas. Calculate the percentage of  $C_{28}H_{34}O_8S_2$  in the portion of Ecamsule Solution taken by the formula:

$$100(562.69/861.07)(V/W)C(r_U/r_S)$$

in which 562.69 and 861.07 are the molecular weights of ecamsule and ecamsule triethanolamine, respectively;  $V$  is the volume, in mL, of the *Assay preparation*;  $W$  is the weight, in mg, of Ecamsule Solution used for the *Assay preparation*;  $C$  is the concentration, in mg per mL, of ecamsule triethanolamine in the *Standard preparation*; and  $r_U$  and  $r_S$  are the sum of peak areas corresponding to trans-trans and cis-trans isomers obtained from the *Assay preparation* and the *Standard preparation*, respectively.

Topic/Question	Contact	Expert Committee
ECAMSULE SOLUTION	<a href="#">Documentary Standards Support</a>	SM32020 Small Molecules 3

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 34(5)

Current DocID: GUID-F330AF2E-C1D4-4F33-908D-9ED8FC938EAB\_2\_en-US

DOI: [https://doi.org/10.31003/USPNF\\_M3063\\_02\\_01](https://doi.org/10.31003/USPNF_M3063_02_01)

DOI ref: [f6khm](#)

OFFICIAL